FRUIT OF THE LOOM® and RECOVER™ Launch Affordable and Sustainable T-shirt Collection
14.9.2022 18:05:00 EEST | Business Wire | Press release
Fruit of the Loom, maker of the iconic FRUIT OF THE LOOM® branded apparel, is partnering with leading materials science company, Recover Textile Systems, S.L., maker of Recover™ fiber, to release a new collection of classic, unisex t-shirts beginning today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005104/en/
Fruit of the Loom® has partnered with Recover™ to release a collection of classic, unisex t-shirts made from responsibly sourced fabric and material. (Photo: Recover™)
With inclusive sizing and responsibly sourced fabric and material, each sustainably designed t-shirt is made with 20% Recover™ best-in-class recycled cotton fiber and is available in eight colors. Each t-shirt is priced at $15. The limited-edition collection will be available for purchase starting August 30 on Fruit.com and Amazon, while supplies last.
The new Recover™ cotton t-shirt collection is one of the many ways Fruit of the Loom is delivering against their goal to “increase sustainable sourcing across key materials” as outlined in the company’s global sustainability plan, Fruitful Futures™. The plan documents specific commitments across three key pillars—People-Centric, Planet-Conscious and Product Authenticity.
“This collection is the latest way Fruit of the Loom is producing more sustainable products across the entire business. As one of the world’s largest manufacturers and marketers of casual wear, we are committed to reducing our environmental impact across the total value chain,” said Mercedes Lopez, Vice President of Corporate Social Responsibility at Fruit of the Loom.
The partnership with Recover and the use of their cotton enables the company to offer a circular sustainable program that utilizes textile production waste to create high-quality recycled cotton fiber. Recover’s proprietary recycled cotton fiber is one of the lowest-impact fibers available in the market, significantly reducing the carbon and water footprint of the apparel produced with the fiber. By partnering with Recover, Fruit of the Loom continues to demonstrate its innovation and commitment to sustainability.
"We're delighted to collaborate with Fruit of the Loom in order to accelerate the adoption of sustainable initiatives within the casual wear segment. The universality of the collection perfectly fits with the values of the Recover™ brand to achieve circular fashion for all,” said Boris Mercier, Senior Vice President of Marketing at Recover.
For more information on the new collection or Fruit of the Loom’s sustainability commitments, visit Fruit.com.
About Recover
Recover is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets. For more information, visit www.recoverfiber.com and follow @recoverfiber on social media.
About Fruit of the Loom
For 170 years, Fruit of the Loom has been a trusted expert in underwear and casual apparel, crafting comfortable, quality products for everybody and every body. We obsess over even the smallest details so people can feel free to focus on the things that matter most to them. And we try not to take ourselves too seriously – it's just more fun that way. For more information about Fruit of the Loom, visit us at Fruit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005104/en/
Contact information
Media Contact
fruitcoreteam@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom